Cubist Systematic Strategies LLC trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,795 shares of the medical research company’s stock after selling 1,253 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Thermo Fisher Scientific were worth $907,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Bank of Nova Scotia Trust Co. bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $106,000. Chicago Partners Investment Group LLC bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $108,000. Shine Investment Advisory Services Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $113,000. Ropes Wealth Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 15.8% during the second quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after purchasing an additional 97 shares in the last quarter. Finally, Atlantic Trust LLC purchased a new position in Thermo Fisher Scientific during the second quarter valued at $138,000. Institutional investors and hedge funds own 86.22% of the company’s stock.
Thermo Fisher Scientific Inc. (TMO) traded up $1.51 during trading hours on Friday, reaching $210.17. The company’s stock had a trading volume of 1,486,494 shares, compared to its average volume of 1,680,000. Thermo Fisher Scientific Inc. has a twelve month low of $140.00 and a twelve month high of $211.54. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85. The company has a market capitalization of $83,840.00, a price-to-earnings ratio of 35.68, a PEG ratio of 1.70 and a beta of 1.06.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The business had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a return on equity of 15.94% and a net margin of 11.73%. Thermo Fisher Scientific’s revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.03 earnings per share. equities analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.29%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
A number of research analysts have issued reports on the company. Zacks Investment Research cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Barclays reiterated an “overweight” rating and set a $215.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Jefferies Group reiterated a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Leerink Swann restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Monday, October 30th. Finally, BTIG Research initiated coverage on Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have assigned a buy rating to the stock. Thermo Fisher Scientific has a consensus rating of “Buy” and an average target price of $212.21.
In other news, CEO Marc N. Casper sold 50,000 shares of the company’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $191.74, for a total value of $9,587,000.00. Following the completion of the transaction, the chief executive officer now owns 302,577 shares of the company’s stock, valued at $58,016,113.98. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.49% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This news story was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright law. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/13/cubist-systematic-strategies-llc-lowers-holdings-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.